The Future of Treatment for Patients With Fabry Disease (FD) and Renal Complications

Released On
April 15, 2021

Expires On
April 15, 2022

Media Type

Completion Time
90 minutes

Cardiology, Genetics, Nephrology, Pediatrics

Genetic Disorders, Heart Disease, Pain, Rare Diseases

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Chiesi.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward nephrologists, cardiologists, gastroenterologists, geneticists, genetic counselors, and any other health care professionals involved in the diagnosis or management of Fabry disease.

Activity Overview

Due to the broad spectrum of phenotypes of Fabry disease and similarities with other disorders, diagnosis is challenging and often delayed. The primary cause of late morbidity and premature mortality in patients with Fabry disease is the irreversible damage that can occur without treatment; therefore, early, definitive diagnosis and timely treatment are crucial. Our overall understanding of Fabry disease has advanced, but greater knowledge of pathophysiological mechanisms, disease manifestations, and effective treatment is needed to improve outcomes among the various Fabry disease subgroups.

This program will look at the differential diagnosis, testing algorithms, and genetics underlying Fabry disease. Expert faculty will review the efficacy and safety of current therapies, with a focus on renal complications, and the results of studies of emerging therapies aimed at improving symptoms, preventing disease progression, and improving patient quality of life.

Learning Objectives

Upon completion of this activity, you should be better able to:

  • Describe the pathophysiology of Fabry disease with respect to the development of renal complications
  • Develop a differential diagnosis for patients presenting with symptoms consistent with Fabry disease
  • Evaluate the efficacy, safety, and limitations of current and emerging therapies for patients with Fabry disease and renal complications
  • Apply clinical trial data and best practice guidelines to the long-term, multidisciplinary management of Fabry disease



Dawn A. Laney, MS, CGC

Assistant Professor/Genetic Counselor
Department of Human Genetics
Emory University
Atlanta, Georgia


Manesh R. Patel, MD

Richard S. Stack Distinguished Professor
Chief, Division of Cardiology
Co-Director Duke Heart Center
Duke Clinical Research Institute
Duke University
Durham, North Carolina


Eric Wallace, MD

Associate Professor
Department of Medicine, Division of Nephrology
Medical Director, Telehealth
Director, Rare Genetic Kidney Disease Clinic
University of Alabama at Birmingham
Birmingham, Alabama


Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

Dawn A. Laney, MS, CGC

  • Grant Funding: Sanofi Genzyme for ISS
  • Research Coordinator for Industry Sponsored Studies: 4D Molecular Therapeutics, Amicus Therapeutics, Sanofi Genzyme, Protalix BioTherapeutics, Sangamo Therapeutics, Takeda/Shire
  • Honoraria/Consulting: Takeda/Shire, Protalix BioTherapeutics, Amicus Therapeutics, Sanofi Genzyme
  • Other: Serves on the Fabry Registry NA Board of Advisors; Co-Founder, ThinkGenetic, Inc.

Manesh R. Patel, MD

  • Grant/Research Support: Bayer, AstraZeneca, Janssen Pharmaceutica, HeartFlow, Procyrion Inc.
  • Consultant: Bayer, Janssen, Mytonomy, Procyrion Inc.

Eric Wallace, MD

  • Grant/Research Support: Sanofi Genzyme, Protalix BioTherapeutics, Idorsia, Baxter Healthcare
  • Consultant: Sanofi Genzyme, Protalix BioTherapeutics, Amicus Therapeutics, AvroBio

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Physicians’ Education Resource®, LLC (PER®), uses a blinded peer-review process. The peer reviewer discloses the following:

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.